Developer docs
API playgroundTry for free, no card

Search company profiles

SCA Pharma

Full company profile

uuid000a4c9

Namestring
SCA Pharma
Legal namestring
SCA Pharmaceuticals, LLC
Websiteurl
scapharma.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SCA Pharma is an FDA 503B outsourcing facility that compounds sterile admixtures and pre-filled syringes for hospital and healthcare facility pharmacies across the United States. The company operates two cGMP-compliant sterile compounding facilities — an Arkansas Manufacturing Facility in Little Rock (8821 Knoedl Court) and a 90,000-square-foot Connecticut Manufacturing Facility in Windsor (755 Rainbow Road) — totaling approximately 120,000 square feet of infrastructure. Licensed in 49 states and Washington, D.C., SCA Pharma serves hospital pharmacy customers through direct enterprise field sales, a customer portal (partner.scapharma.com), channel partnerships with Vizient and Medigi, and processes approximately 5,800 monthly shipments across a catalog of roughly 200 National Drug Codes spanning 15 therapeutic categories (firmographics and company history describe an operational founding in 2017 following an initial investment from Enhanced Healthcare Partners, though firmographic records list 2009 for the legal entity; this conflict is noted and not resolved by the available data).

The company's product portfolio covers critical care, labor and delivery, anesthesia, and pain management applications, with named products including Hydromorphone HCl, Sugammadex, Ketamine HCl, and Potassium Phosphate. SCA Pharma was the first 503B outsourcing facility to embed Kit Check RFID tags on all products and operates advanced rapid microbiological testing infrastructure including the Celsis rapid detection platform, Charles River Endosafe-MCS endotoxin testing, and Rapid Micro Biosystems Growth Direct, supported by HPLC/UPLC chromatography for assay and impurity determination. Quality operations are managed through a validated MasterControl electronic Quality Management System aligned with ICH Q10 and ICH Q9(R1) principles and staffed by 90+ quality personnel and 20 licensed pharmacists.

SCA Pharma generates revenue through the sale of compounded pharmaceutical products to hospital and healthcare facility pharmacies via direct sales teams, an online customer portal, and third-party purchasing platforms. A multi-year agreement with Vizient — a healthcare performance improvement company whose member network includes over 60% of U.S. healthcare organizations — provides significant distribution reach. Extended Beyond Use Date (BUD) programs — covering 69 products with BUDs up to 180 days — and guaranteed next-business-day shipping on Buy & Ship Now orders support inventory efficiency for pharmacy customers. SCA Pharma was acquired in January 2021 by The Vistria Group and Excellere Partners and is led by CEO Scott Luce, supported by a leadership team including COO Matt White (PharmD), CQO Ken Bonnell (formerly of Aldevron/Danaher, Merck, and PCI Pharma), CHRO Steven Dufort, and VP of Sales & Customer Experience Jessica Wrentz.

Short descriptiontext

SCA Pharma is an FDA 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ready-to-use medications for U.S. hospital and healthcare facility pharmacies. It operates two cGMP-compliant compounding facilities and distributes through Vizient GPO and Medigi platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLittle Rock, United States
HQ citystring
Little Rock
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile compounding services, FDA 503B outsourcing, pre-filled syringe manufacturing, hospital pharmacy medications, ready-to-use injectables
Industry3 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
503B Sterile Compounded Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Compounded Pharmaceutical Products
TypeOne Time License
Description

SCA Pharma generates revenue through the sale of FDA 503B compliant sterile compounded pharmaceuticals including sterile admixtures, pre-filled syringes, and ready-to-use medications to hospital and healthcare facility pharmacies. Products are sold through direct sales teams, customer portal, and distribution partnerships.

scapharma.com
2Platform Distribution
TypeTransaction Fee
Description

Revenue from distributing core pharmaceutical products through third-party purchasing platforms such as Medigi, expanding market reach beyond direct customer relationships.

scapharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SCA Pharma is an FDA 503B outsourcing facility that compounds and supplies sterile admixtures (IV bags) and pre-filled syringes — including ready-to-use and drug-shortage medications — to hospital and healthcare facility pharmacies from cGMP-compliant facilities in Little Rock, Arkansas and Windsor, Connecticut. The portfolio comprises approximately 200 product NDCs across 15 therapeutic categories, with extended Beyond Use Dating, RFID-enabled medication intelligence, and rapid sterility and endotoxin testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Produced over 4 million patient doses in 2017 from the Little Rock facility alone
+2 more records
Product overview1 text field

SCA Pharma is an FDA 503B outsourcing facility providing hospital and healthcare facility pharmacies with sterile compounded medications. The company operates two state-of-the-art facilities (Little Rock, Arkansas and Windsor, Connecticut) and offers a portfolio centered on sterile admixtures (IV bags) and pre-filled syringes. The product portfolio includes approximately 200 Product NDCs across 15 product categories, serving critical care, labor and delivery, anesthesia, and pain management therapeutic areas. Key products include Hydromorphone HCl (pain management), Sugammadex (neuromuscular blockade reversal), and Ketamine HCl (anesthesia), as well as ready-to-use and drug-shortage medications. The company differentiates through cGMP compliance, extended Beyond Use Dating (BUD) programs, RFID-enabled medication intelligence via Kit Check, and multi-platform distribution through Vizient, Medigi, and direct sales channels.

Product and service6 records
1Sterile Admixtures (IV Bags)
Category503B sterile admixtures
Description

Compounded sterile admixture IV bag products in 0.9% Sodium Chloride and other diluents spanning pain management, electrolyte replacement, and critical care — ready-to-use for hospital administration.

2Pre-filled Syringes
Category503B pre-filled syringes
Description

Pre-filled syringes in various concentrations and volumes (e.g., 50 mg/5 mL) for anesthesia, neuromuscular blockade reversal, pain management, and other critical care applications — ready-to-use and RFID-tagged for medication intelligence.

3Hydromorphone HCl Products
Category503B sterile admixtures (pain management)
Description

Hydromorphone HCl sterile admixtures in 0.9% Sodium Chloride in multiple concentrations and bag sizes for hospital pain management.

4Sugammadex Products
Category503B pre-filled syringes (anesthesia)
Description

Sugammadex sterile pre-filled syringes for reversal of neuromuscular blockade, with extended Beyond Use Dating (up to 120 days) for inventory flexibility.

5Ketamine HCl
Category503B pre-filled syringes (anesthesia / pain management)
Description

Ketamine HCl 50 mg/mL pre-filled syringe (1 mL in 3 mL syringe) for anesthesia and pain management, with Beyond Use Dating up to 180 days.

6Potassium Phosphate
Category503B sterile admixtures (electrolyte replacement)
Description

Potassium Phosphate 15 mMol in 0.9% Sodium Chloride 250 mL IV bag for electrolyte replacement in hospitalized patients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-10
Description

SCA Pharma expanded distribution of core pharmaceutical products to Medigi as an alternate purchasing location. This partnership ensures healthcare professionals can access SCA Pharma's trusted offerings through a broader network of purchasing platforms, improving accessibility and supporting continuity of care.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-01
Description

SCA Pharma was awarded a multi-year agreement by Vizient for its full range of 503B ready-to-use products. Vizient is one of the nation's leading healthcare performance improvement companies trusted by over 60% of U.S. health care organizations. An independent third-party cGMP assessment was completed as a requirement for the contract, confirming both SCA facilities produce high-quality, safe, and efficacious products.

3Kit Check
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-09-10
Description

SCA Pharma partnered with Kit Check, a leader in automated and intelligent medication management solutions. SCA Pharma was the first 503B outsourcing facility to use Kit Check's embedded RFID tag on all products, providing medication intelligence and enhancing safety verification for customers.

scapharma.com
4DoseID Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-08-31
Description

SCA Pharma joined the DoseID consortium, the first member-driven industry consortium dedicated to the use of radio-frequency identification (RFID) technology in healthcare, with the goal of ensuring performance, quality, and accuracy of RFID-tagged drug products.

scapharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-16
Description

During COVID-19 pandemic, SCA Pharma partnered with Bausch Advanced Technologies to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.

Strategic tierMinorTypeGTM or Marketing Partner
Description

SCA Pharma participates in Health Connect Partners Hospital Pharmacy conferences (spring and fall), exhibiting and sharing information about quality initiatives, product portfolio, and facility virtual tours.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

QuVa Pharma is a leading FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes for hospital and health-system pharmacies. QuVa competes head-to-head with SCA across the same 503B product categories, customer base (US hospitals), and regulatory framework, making it the most direct comparable.

TypeDirect peer
Description

Leiters Health is an FDA 503B outsourcing facility providing ready-to-use sterile admixtures, pre-filled syringes, and ophthalmic preparations to hospital and health-system pharmacies. Directly comparable to SCA on regulatory regime, product format (sterile admixtures and prefilled syringes), and target customer (US hospital pharmacies).

TypeDirect peer
Description

CAPS is one of the largest 503B and centralized admixture compounding pharmacy networks in the U.S., serving hospital pharmacies with compounded sterile preparations. Comparable to SCA in regulatory positioning (503B), service offering (sterile admixtures), and customer base (US hospitals).

TypeDirect peer
Description

Pharmedium (a Cencora/AmerisourceBergen business) operates a national network of 503B compounding pharmacies producing sterile admixtures and prefilled syringes for hospitals. A direct competitor to SCA in 503B sterile outsourcing with similar product categories, national distribution, and GPO-driven hospital customer base.

TypeEmerging player
Description

Olympia Pharmaceuticals operates as a 503B outsourcing facility offering compounded sterile preparations and repackaged pharmaceutical products to hospital and clinical customers. Smaller and more regionally focused than SCA but competing in the same 503B regulatory and product category.

TypeEmerging player
Description

Wells Pharma of Houston is an FDA 503B registered outsourcing facility providing sterile admixtures and pre-filled syringes to hospital pharmacies. A smaller 503B peer with overlapping product format and customer base as SCA, though with a more limited national footprint.

TypeBroad incumbent
Description

B. Braun is a major medical device and pharmaceutical solutions company with a large IV solutions, infusion therapy, and sterile compounding/admixture portfolio serving US hospitals. Comparable as a broader incumbent that competes for hospital pharmacy wallet share, particularly on IV solutions and compounded sterile preparations.

TypeBroad incumbent
Description

Baxter is a global healthcare company with significant hospital pharmacy and sterile injectable/IV solutions franchises, including a broader portfolio than SCA. Relevant incumbent competitor in hospital pharmacy sourcing decisions, especially for IV admixtures and ready-to-administer products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SCA Pharma

503B Sterile Compounded Pharmaceuticalsscapharma.com

SCA Pharma is an FDA 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ready-to-use medications for U.S. hospital and healthcare facility pharmacies. It operates two cGMP-compliant compounding facilities and distributes through Vizient GPO and Medigi platforms.

What SCA Pharma does

SCA Pharma is an FDA 503B outsourcing facility that compounds sterile admixtures and pre-filled syringes for hospital and healthcare facility pharmacies across the United States. The company operates two cGMP-compliant sterile compounding facilities — an Arkansas Manufacturing Facility in Little Rock (8821 Knoedl Court) and a 90,000-square-foot Connecticut Manufacturing Facility in Windsor (755 Rainbow Road) — totaling approximately 120,000 square feet of infrastructure. Licensed in 49 states and Washington, D.C., SCA Pharma serves hospital pharmacy customers through direct enterprise field sales, a customer portal (partner.scapharma.com), channel partnerships with Vizient and Medigi, and processes approximately 5,800 monthly shipments across a catalog of roughly 200 National Drug Codes spanning 15 therapeutic categories (firmographics and company history describe an operational founding in 2017 following an initial investment from Enhanced Healthcare Partners, though firmographic records list 2009 for the legal entity; this conflict is noted and not resolved by the available data).

The company's product portfolio covers critical care, labor and delivery, anesthesia, and pain management applications, with named products including Hydromorphone HCl, Sugammadex, Ketamine HCl, and Potassium Phosphate. SCA Pharma was the first 503B outsourcing facility to embed Kit Check RFID tags on all products and operates advanced rapid microbiological testing infrastructure including the Celsis rapid detection platform, Charles River Endosafe-MCS endotoxin testing, and Rapid Micro Biosystems Growth Direct, supported by HPLC/UPLC chromatography for assay and impurity determination. Quality operations are managed through a validated MasterControl electronic Quality Management System aligned with ICH Q10 and ICH Q9(R1) principles and staffed by 90+ quality personnel and 20 licensed pharmacists.

SCA Pharma generates revenue through the sale of compounded pharmaceutical products to hospital and healthcare facility pharmacies via direct sales teams, an online customer portal, and third-party purchasing platforms. A multi-year agreement with Vizient — a healthcare performance improvement company whose member network includes over 60% of U.S. healthcare organizations — provides significant distribution reach. Extended Beyond Use Date (BUD) programs — covering 69 products with BUDs up to 180 days — and guaranteed next-business-day shipping on Buy & Ship Now orders support inventory efficiency for pharmacy customers. SCA Pharma was acquired in January 2021 by The Vistria Group and Excellere Partners and is led by CEO Scott Luce, supported by a leadership team including COO Matt White (PharmD), CQO Ken Bonnell (formerly of Aldevron/Danaher, Merck, and PCI Pharma), CHRO Steven Dufort, and VP of Sales & Customer Experience Jessica Wrentz.

SCA Pharma firmographics

Firmographics
Name
SCA Pharma
Legal name
SCA Pharmaceuticals, LLC
Website
https://scapharma.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
501–1,000 employees
Short description
SCA Pharma is an FDA 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ready-to-use medications for U.S. hospital and healthcare facility pharmacies. It operates two cGMP-compliant compounding facilities and distributes through Vizient GPO and Medigi platforms.
Ownership category
akta.pro rank

SCA Pharma industry classification

Industry
Product category
503B Sterile Compounded Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)

Keywords

  • Sterile compounding services
  • FDA 503B outsourcing
  • Pre-filled syringe manufacturing
  • Hospital pharmacy medications
  • Ready-to-use injectables

Where SCA Pharma is headquartered

Location

Headquarters

HQ city
Little Rock
HQ country
United States
HQ region
North America

Offices3 records

Markets served

SCA Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Compounded Pharmaceutical Products: SCA Pharma generates revenue through the sale of FDA 503B compliant sterile compounded pharmaceuticals including sterile admixtures, pre-filled syringes, and ready-to-use medications to hospital and healthcare facility pharmacies. Products are sold through direct sales teams, customer portal, and distribution partnerships.
  2. Platform Distribution: Revenue from distributing core pharmaceutical products through third-party purchasing platforms such as Medigi, expanding market reach beyond direct customer relationships.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

SCA Pharma product offering

Product offering

Core offering

SCA Pharma is an FDA 503B outsourcing facility that compounds and supplies sterile admixtures (IV bags) and pre-filled syringes — including ready-to-use and drug-shortage medications — to hospital and healthcare facility pharmacies from cGMP-compliant facilities in Little Rock, Arkansas and Windsor, Connecticut. The portfolio comprises approximately 200 product NDCs across 15 therapeutic categories, with extended Beyond Use Dating, RFID-enabled medication intelligence, and rapid sterility and endotoxin testing.

Product overview

SCA Pharma is an FDA 503B outsourcing facility providing hospital and healthcare facility pharmacies with sterile compounded medications. The company operates two state-of-the-art facilities (Little Rock, Arkansas and Windsor, Connecticut) and offers a portfolio centered on sterile admixtures (IV bags) and pre-filled syringes. The product portfolio includes approximately 200 Product NDCs across 15 product categories, serving critical care, labor and delivery, anesthesia, and pain management therapeutic areas. Key products include Hydromorphone HCl (pain management), Sugammadex (neuromuscular blockade reversal), and Ketamine HCl (anesthesia), as well as ready-to-use and drug-shortage medications. The company differentiates through cGMP compliance, extended Beyond Use Dating (BUD) programs, RFID-enabled medication intelligence via Kit Check, and multi-platform distribution through Vizient, Medigi, and direct sales channels.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sterile Admixtures (IV Bags) Compounded sterile admixture IV bag products in 0.9% Sodium Chloride and other diluents spanning pain management, electrolyte replacement, and critical care — ready-to-use for hospital administration.
  • Pre-filled Syringes Pre-filled syringes in various concentrations and volumes (e.g., 50 mg/5 mL) for anesthesia, neuromuscular blockade reversal, pain management, and other critical care applications — ready-to-use and RFID-tagged for medication intelligence.
  • Hydromorphone HCl Products Hydromorphone HCl sterile admixtures in 0.9% Sodium Chloride in multiple concentrations and bag sizes for hospital pain management.
  • Sugammadex Products Sugammadex sterile pre-filled syringes for reversal of neuromuscular blockade, with extended Beyond Use Dating (up to 120 days) for inventory flexibility.
  • Ketamine HCl Ketamine HCl 50 mg/mL pre-filled syringe (1 mL in 3 mL syringe) for anesthesia and pain management, with Beyond Use Dating up to 180 days.
  • Potassium Phosphate Potassium Phosphate 15 mMol in 0.9% Sodium Chloride 250 mL IV bag for electrolyte replacement in hospitalized patients.

Quantifiable outcome

  • Produced over 4 million patient doses in 2017 from the Little Rock facility alone
  • +2 more outcomes

Companies that use SCA Pharma

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

SCA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

SCA Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • MedigicoreChannel Partner/ Reseller/ Distributor · 10 September 2025SCA Pharma expanded distribution of core pharmaceutical products to Medigi as an alternate purchasing location. This partnership ensures healthcare professionals can access SCA Pharma's trusted offerings through a broader network of purchasing platforms, improving accessibility and supporting continuity of care.
  • VizientcoreChannel Partner/ Reseller/ Distributor · 1 November 2022SCA Pharma was awarded a multi-year agreement by Vizient for its full range of 503B ready-to-use products. Vizient is one of the nation's leading healthcare performance improvement companies trusted by over 60% of U.S. health care organizations. An independent third-party cGMP assessment was completed as a requirement for the contract, confirming both SCA facilities produce high-quality, safe, and efficacious products.
  • Kit CheckcoreTechnology or Integration · 10 September 2020SCA Pharma partnered with Kit Check, a leader in automated and intelligent medication management solutions. SCA Pharma was the first 503B outsourcing facility to use Kit Check's embedded RFID tag on all products, providing medication intelligence and enhancing safety verification for customers.
  • DoseID ConsortiumminorStrategic or Co-development Partner · 31 August 2020SCA Pharma joined the DoseID consortium, the first member-driven industry consortium dedicated to the use of radio-frequency identification (RFID) technology in healthcare, with the goal of ensuring performance, quality, and accuracy of RFID-tagged drug products.
  • Bausch Advanced TechnologiesminorStrategic or Co-development Partner · 16 April 2020During COVID-19 pandemic, SCA Pharma partnered with Bausch Advanced Technologies to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.
  • Health Connect PartnersminorGTM or Marketing PartnerSCA Pharma participates in Health Connect Partners Hospital Pharmacy conferences (spring and fall), exhibiting and sharing information about quality initiatives, product portfolio, and facility virtual tours.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

SCA Pharma competitors and assessment

Company assessment

Direct peers

  • QuVa Pharma: QuVa Pharma is a leading FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes for hospital and health-system pharmacies. QuVa competes head-to-head with SCA across the same 503B product categories, customer base (US hospitals), and regulatory framework, making it the most direct comparable.
  • Leiters Health: Leiters Health is an FDA 503B outsourcing facility providing ready-to-use sterile admixtures, pre-filled syringes, and ophthalmic preparations to hospital and health-system pharmacies. Directly comparable to SCA on regulatory regime, product format (sterile admixtures and prefilled syringes), and target customer (US hospital pharmacies).
  • Central Admixture Pharmacy Services (CAPS): CAPS is one of the largest 503B and centralized admixture compounding pharmacy networks in the U.S., serving hospital pharmacies with compounded sterile preparations. Comparable to SCA in regulatory positioning (503B), service offering (sterile admixtures), and customer base (US hospitals).
  • Pharmedium Services: Pharmedium (a Cencora/AmerisourceBergen business) operates a national network of 503B compounding pharmacies producing sterile admixtures and prefilled syringes for hospitals. A direct competitor to SCA in 503B sterile outsourcing with similar product categories, national distribution, and GPO-driven hospital customer base.

Emerging players

  • Olympia Pharmaceuticals: Olympia Pharmaceuticals operates as a 503B outsourcing facility offering compounded sterile preparations and repackaged pharmaceutical products to hospital and clinical customers. Smaller and more regionally focused than SCA but competing in the same 503B regulatory and product category.
  • Wells Pharma of Houston: Wells Pharma of Houston is an FDA 503B registered outsourcing facility providing sterile admixtures and pre-filled syringes to hospital pharmacies. A smaller 503B peer with overlapping product format and customer base as SCA, though with a more limited national footprint.

Broad incumbents

  • B. Braun Medical: B. Braun is a major medical device and pharmaceutical solutions company with a large IV solutions, infusion therapy, and sterile compounding/admixture portfolio serving US hospitals. Comparable as a broader incumbent that competes for hospital pharmacy wallet share, particularly on IV solutions and compounded sterile preparations.
  • Baxter International: Baxter is a global healthcare company with significant hospital pharmacy and sterile injectable/IV solutions franchises, including a broader portfolio than SCA. Relevant incumbent competitor in hospital pharmacy sourcing decisions, especially for IV admixtures and ready-to-administer products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

SCA Pharma social profiles

Digital presence

SCA Pharma compliance and trust

Trust signal

Compliance6 records

SCA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SCA Pharma leadership team

Management profile

Number of profiles

Profiles7 records

SCA Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SCA Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCA Pharma

What does SCA Pharma do?

SCA Pharma is an FDA 503B outsourcing facility that compounds and supplies sterile admixtures (IV bags) and pre-filled syringes — including ready-to-use and drug-shortage medications — to hospital and healthcare facility pharmacies from cGMP-compliant facilities in Little Rock, Arkansas and Windsor, Connecticut. The portfolio comprises approximately 200 product NDCs across 15 therapeutic categories, with extended Beyond Use Dating, RFID-enabled medication intelligence, and rapid sterility and endotoxin testing.

Is SCA Pharma a public or private company?

SCA Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was SCA Pharma founded?

SCA Pharma was founded in 2017. It employs 501 to 1,000 people.

Where is SCA Pharma based?

SCA Pharma is headquartered in Little Rock, United States, in the North America region.

How does SCA Pharma make money?

Two revenue lines are on record. Compounded Pharmaceutical Products are the primary driver. The others are platform Distribution.

Who are SCA Pharma's main competitors?

Direct peers on record are QuVa Pharma, Leiters Health, Central Admixture Pharmacy Services (CAPS) and Pharmedium Services. Emerging players are Olympia Pharmaceuticals and Wells Pharma of Houston. Broad incumbents are B. Braun Medical and Baxter International.

Does SCA Pharma have an API?

No public API is recorded for SCA Pharma.

What industry is SCA Pharma in?

SCA Pharma's product category is 503B Sterile Compounded Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Towards HealthcareU.S. 503B Compounding Pharmacies Market to Reach USD 1.35 Billion in 2026The U.S. 503B compounding pharmacies market was valued at USD 1.25 billion in 2025 and is projected to grow to USD 1.35 billion in 2026 and USD 2.61 billion by 2035, representing a CAGR of 7.63% during the forecast period. Sterile compounded drugs dominate the market at 68% share, while injections and infusions lead formulation types at 38%, with pain management being the largest therapeutic application segment at 24%. Key players in the market include SCA Pharma, Nephron Pharmaceuticals Corporation, Athenex, Olympia Pharmacy, and Fagron Compounding Pharmacies, with recent activity including Revelation Pharma's acquisition of Cascade Specialty Pharmacy and Olympia Pharmaceuticals' expansion into Alabama.PR NewswireSCA Pharma Names Hugh O'Neill as Chief Commercial OfficerSCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry, has appointed Hugh O'Neill as Chief Commercial Officer. O'Neill brings over 30 years of pharmaceutical industry experience, most recently serving as Executive Vice President at Mallinckrodt Pharmaceuticals, and previously held leadership roles at Sanofi, Pharmacia, Novartis, Forest Laboratories, and Sandoz. The appointment is intended to support SCA Pharma's accelerated growth strategy as the company aims to meet increasing market demand for its products and services.PR NewswireSCA Pharma Awarded Multi-Year Contract with Vizient, Supporting Better Drug AccessibilitySCA Pharma has been awarded a multi-year agreement by Vizient, one of the nation's leading healthcare performance improvement companies trusted by over 60% of U.S. health care organizations, for its full range of 503B ready-to-use compounded pharmaceutical products. An independent third-party assessment confirmed that SCA Pharma's facilities are producing high-quality, safe, and efficacious products in compliance with 503B requirements, with expansion projects underway to increase production volume. The partnership is designed to improve hospital access to critical medications and support pharmacy operations nationwide.PR NewswireSCA Pharma Names Louis Pace as Chief Financial Officer and Chief Information OfficerSCA Pharma announced the appointment of Louis Pace as Chief Financial Officer and Chief Information Officer, bringing over 30 years of experience including his recent role as CFO at Orchid Orthopedic Solutions. CEO Scott Luce stated that the hire aligns with SCA Pharma's strategic focus on accelerating growth and providing innovative solutions for 503B customers. Pace will oversee finance, accounting, and information technology teams while pursuing internal and external business opportunities.FiercePharmaCompounder SCA Pharma plots double expansion to boost capacity for scarce hospital medsSCA Pharma is expanding two production plants to boost capacity for scarce hospital meds. It will double its Windsor, Connecticut site to 150,000 square feet and invest $10 million in a new sterile injectables facility at its Little Rock airport plant, doubling its workforce. The expansions follow FDA easing of compounding rules during the pandemic.Talk Business & PoliticsSCA Pharma to expand production facility in LR, could double workforce of 180 - Talk Business & PoliticsSCA Pharma announced a $10 million expansion in Little Rock, potentially doubling its 180-person workforce and adding 20,000 square feet. The company also plans a 40% expansion of its Windsor, Conn. facility. The Little Rock expansion will create technical and highly-skilled jobs.